BRET HAFEN: Open Payments
NPI 1982060828 · LAYTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$217,976 in 493 payments from 11 companies in 2025. Trend: 2023 $42,690 · 2024 $116,914 · 2025 $217,976
Speaker / faculty: $162,389Travel & lodging: $34,000Consulting: $12,820Food & beverage: $8,762Education: $5
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 209 | $108,582 |
| Alkermes, Inc. | 91 | $36,850 |
| ABBVIE INC. | 95 | $29,881 |
| Janssen Pharmaceuticals, Inc | 49 | $29,083 |
| E.R. Squibb & Sons, L.L.C. | 27 | $7,598 |
| Otsuka America Pharmaceutical, Inc. | 13 | $5,484 |
| Janssen Scientific Affairs, LLC | 2 | $219 |
| Neurocrine BioSciences, Inc. | 3 | $145 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $71 |
| Neuronetics, Inc. | 2 | $47 |
Products named: CAPLYTA, LYBALVI, INVEGA SUSTENNA, VRAYLAR, ABILIFY MAINTENA, VIVITROL, REXULTI, COBENFY.
Industry payments across UT — which companies pay providers there.
